Indications of DC-CIK biotherapy Early-stage tumor patients: In early-stage tumor patients, when the tumor is diagnosed and the tumor cells have not metastasized, CLS treatment alone or combined with surgical treatment can accurately and systematically kill the tumor cells, and achieve the goal that one-third of the cancers in early stage can be cured. People with metastasis after radiotherapy and chemotherapy: When tumor cell metastasis occurs during postoperative radiotherapy and chemotherapy, DC-CIK treatment combined with radiotherapy can reduce the toxic side effects of radiotherapy and increase the sensitivity of radiotherapy; combined with chemotherapy can reduce the side effects of drugs occurring in multiple systems such as digestion and blood, and enhance the inhibitory or killing effect on tumor tissues. Combined treatment can comprehensively remove residual tumor cells, improve immune function and prevent metastasis. Patients with advanced disease: For patients with advanced disease who cannot tolerate radiotherapy, CLS treatment can alleviate all kinds of pain and effectively prolong the life cycle of patients. Biological DC-CIK treatment technology is suitable for patients including malignant melanoma, prostate cancer, kidney cancer, bladder cancer, ovarian cancer, colon cancer, rectal cancer, breast cancer, cervical cancer, lung cancer, laryngeal cancer, nasopharyngeal cancer, pancreatic cancer, liver cancer, stomach cancer, and other hematological tumors with autologous stem cell transplantation or tiny lesion residue after radiotherapy (especially suitable for comprehensive treatment combined with other conventional treatment). It can prevent recurrence and metastasis after surgery, and achieve the purpose of prolonging the survival period, improving the quality of life and inhibiting the deterioration of tumor.